Nivolumab Injection

DRUG12 trials

Sponsors

Melbourne Health, UNICANCER, Institut Curie, Intergroupe Francophone de Cancerologie Thoracique, Robert L. Ferris, MD, PhD

Conditions

COVID19- Infection With SARS-CoV-2 VirusCarcinoma, Squamous Cell of Head and NeckCervical CancerHIV/AIDSHaematological MalignancyLocally Advanced Cervical CancerMalignant Pleural MesotheliomaMelanoma

Phase 1

Nivolumab in Association With Radiotherapy and Cisplatin in Locally Advanced Cervical Cancers Followed by Adjuvant Nivolumab for up to 6 Months (NiCOL)

CompletedNCT03298893

Institut CurieCervical Cancer, Locally Advanced Cervical Cancer

Start: 2017-11-27End: 2022-03-07Updated: 2025-09-19

Safety and Efficacy of Sonocloud Device Combined With Nivolumab in Brain Metastases From Patients With Melanoma

Assistance Publique - Hôpitaux de ParisMelanoma, Metastatic Melanoma

Start: 2019-10-24End: 2023-07-05Target: 21Updated: 2020-08-20

Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors

Active, not recruitingNCT04165330

Sarcoma Oncology Research Center, LLCNon Small Cell Lung Cancer, Small Cell Lung Cancer, Soft Tissue Sarcoma +1

Start: 2019-10-17End: 2028-03-31Target: 56Updated: 2025-02-24

Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer

RecruitingNCT06008925

CNBG-Virogin Biotech (Shanghai) Ltd.Metastatic Gastric Cancer

Start: 2022-11-17End: 2026-06-30Target: 43Updated: 2023-08-24

Phase 2

Nivolumab for Relapsed or Residual Haematological Malignancies After Allogeneic Stem Cell Transplantation

Melbourne HealthHaematological Malignancy

Start: 2017-05-08End: 2022-03-01Target: 14Updated: 2021-09-23

Nivolumab in Recurrent and/or Metastatic SCCHN

CompletedNCT03226756

UNICANCERRecurrent and/or Metastatic Platinum-refractory SCCHN

Start: 2017-07-07End: 2022-05-31Updated: 2023-01-18

Immunotherapy by Nivolumab for HIV+ Patients

CompletedNCT03304093

Intergroupe Francophone de Cancerologie ThoraciqueHIV/AIDS, Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer Stage IIIB

Start: 2017-10-19End: 2022-02-18Updated: 2023-05-12

Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer

CompletedNCT03715946

Robert L. Ferris, MD, PhDCarcinoma, Squamous Cell of Head and Neck, Oropharynx Squamous Cell Carcinoma

Start: 2018-11-16End: 2024-03-31Updated: 2025-01-13

Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma

Active, not recruitingNCT03918252

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsMesothelioma

Start: 2019-10-02End: 2027-06-30Updated: 2025-06-26

Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery

CompletedNCT04177953

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestPleural Mesothelioma Malignant

Start: 2019-02-04End: 2025-01-30Updated: 2025-02-06

Trial Evaluating Efficacy and Safety of Nivolumab (Optivo®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort.

Assistance Publique - Hôpitaux de ParisCOVID19- Infection With SARS-CoV-2 Virus

Start: 2020-04-15End: 2020-09-30Target: 92Updated: 2020-04-14

The IMmunotherapy Pleural 5-ALA PDT

RecruitingNCT04400539

University Hospital, LilleMalignant Pleural Mesothelioma, Mesotheliomas Pleural

Start: 2022-05-09End: 2026-05-09Target: 20Updated: 2025-09-25

Related Papers

Abstract 1037: Single cell and spatially resolved determinants of the clinical outcome of patients (pts) treated with locally advanced/metastatic head and neck squamous cell carcinoma (LA/M SCCHN) treated with immunotherapy (IO)

Cancer Research2026-04-03

Abstract 1034: Transcriptomic and genomic signatures associated with response or resistance to immunotherapy(IO) in locally advanced/metastatic (LA/M) head and neck squamous cell carcinoma (HNSCC) patients

Cancer Research2026-04-03

Abstract 4724: Elevated plasma trimethylamine-N-oxide (TMAO) levels correlate with better clinical and molecular responses in immunotherapy-treated resectable gastroesophageal cancer and pleural mesothelioma

Cancer Research2026-04-03

Abstract 1129: Analytical and clinical sensitivity of tumor-informed and tumor-naïve ctDNA residual disease detection during neoadjuvant immune checkpoint inhibition in resectable cancers

Cancer Research2026-04-03

Perioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses

Nature Medicine2025-09-085 citations

ctDNA tumor fraction (TF) to predict response to nivolumab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): An analysis of the multicentric phase 2 TOPNIVO trial.

Journal of Clinical Oncology2025-05-28

Toripalimab combined with definitive chemoradiotherapy for locally advanced cervical squamous cell carcinoma patients (TRACE): A single-arm, phase I/II trial.

2024-10-033 citations

Oncolytic virotherapy stimulates anti‑tumor immune response and demonstrates activity in advanced sarcoma: Report of two cases

Oncology Letters2024-04-032 citations

Repeated blood-brain barrier opening with a nine-emitter implantable ultrasound device in combination with carboplatin in recurrent glioblastoma: a phase I/II clinical trial.

2024-02-2366 citations

Nivolumab plus chemoradiotherapy in locally-advanced cervical cancer: the NICOL phase 1 trial

Nature Communications2023-06-2247 citations

Nivolumab with chemotherapy in pleural mesothelioma after surgery: The NICITA trial.

Journal of Clinical Oncology2023-06-011 citations

Phase II trial of adjuvant de-escalated radiation + adjuvant nivolumab for intermediate-high risk P16+ oropharynx cancer.

Journal of Clinical Oncology2023-06-011 citations

Combination of nivolumab with chemoradiotherapy for locally advanced cervical cancer: NiCOL phase I trial.

Journal of Clinical Oncology2022-06-018 citations

Resolving sticky relationships between platelets and lymphocytes in <scp>COVID‐19</scp>: A role for checkpoint inhibitors?

British Journal of Haematology2022-02-082 citations

A Phase II Trial of Nivolumab With Chemotherapy Followed by Maintenance Nivolumab in Patients With Pleural Mesothelioma After Surgery: The NICITA Study Protocol.

2020-10-1412 citations

Trial in progress: Neoadjuvant immune checkpoint blockade in resectable malignant pleural mesothelioma.

Journal of Clinical Oncology2020-05-201 citations

Immunotherapy Use in Patients with HIV and Non-Small-Cell Lung Cancer: Current Data

Journal of Immunotherapy and Precision Oncology2019-07-293 citations

A safety study of nivolumab in patients with recurrent and/or metastatic platinum-refractory squamous cell carcinoma of the head and neck (R/M SCCHN): Interim analysis on 199 patients—The TOPNIVO study on behalf of the GORTEC and the Unicancer Head & Neck Group.

Journal of Clinical Oncology2019-05-206 citations

TOPNIVO: A safety study of nivolumab in patients with recurrent and/or metastatic platinum-refractory squamous cell carcinoma of the head and neck (R/M SCCHN): First results on behalf of the UNICANCER Head&Neck Group and the GORTEC

Annals of Oncology2018-10-011 citations

New Treatments for Relapsed Hematologic Malignancies After alloHCT

Oncology Times2018-09-261 citations